Amedeo Smart

Free Medical Literature Service

 

Amedeo

Vaccines
  Free Subscription

Articles published in
Lancet
    September 2025
  1. KUEHN R, Rahden P, Hussain HS, Karkey A, et al
    Enteric (typhoid and paratyphoid) fever.
    Lancet. 2025;406:1283-1294.
    >> Share

    August 2025
  2. LEE K, Kohler J
    Good governance essential to expanding vaccine capacity and strengthening public trust.
    Lancet. 2025 Aug 29:S0140-6736(25)01681-2. doi: 10.1016/S0140-6736(25)01681.
    >> Share

  3. ANDERSON CS, Hua C, Wang Z, Wang C, et al
    Influenza vaccination to improve outcomes for patients with acute heart failure (PANDA II): a multiregional, seasonal, hospital-based, cluster-randomised, controlled trial in China.
    Lancet. 2025 Aug 28:S0140-6736(25)01485-0. doi: 10.1016/S0140-6736(25)01485.
    >> Share

  4. BHATT AS, Vardeny O
    Influenza vaccination in heart failure: a shot worth taking?
    Lancet. 2025 Aug 28:S0140-6736(25)01679-4. doi: 10.1016/S0140-6736(25)01679.
    >> Share

  5. KULKARNI PS, Potey AV, Kapse D, Bhamare C, et al
    Post-exposure prophylaxis regimen of rabies monoclonal antibody and vaccine in category 3 potential exposure patients: a phase 4, open-label, randomised, active-controlled trial.
    Lancet. 2025;406:627-635.
    >> Share

  6. WAGNER J
    Respiratory syncytial virus vaccine effectiveness.
    Lancet. 2025;406:599.
    >> Share

  7. PAYNE AB, Mitchell PK, Watts JA, Link-Gelles R, et al
    Respiratory syncytial virus vaccine effectiveness - Authors' reply.
    Lancet. 2025;406:599-600.
    >> Share

    July 2025
  8. LARSON HJ, Piatek SJ
    A crisis of credibility: the global cost of US vaccine misinformation.
    Lancet. 2025 Jul 30:S0140-6736(25)01495-3. doi: 10.1016/S0140-6736(25)01495.
    >> Share

    June 2025
  9. FANG H
    Strengthening global routine childhood vaccination.
    Lancet. 2025 Jun 24:S0140-6736(25)01278-4. doi: 10.1016/S0140-6736(25)01278.
    >> Share


  10. Global, regional, and national trends in routine childhood vaccination coverage from 1980 to 2023 with forecasts to 2030: a systematic analysis for the Global Burden of Disease Study 2023.
    Lancet. 2025 Jun 24:S0140-6736(25)01037-2. doi: 10.1016/S0140-6736(25)01037.
    >> Share

  11. PAIL O, Lin MJ, Anagnostou T, Brown BD, et al
    Cancer vaccines and the future of immunotherapy.
    Lancet. 2025 Jun 17:S0140-6736(25)00553-7. doi: 10.1016/S0140-6736(25)00553.
    >> Share

  12. HIRANI K, Rwebembera J, Webb R, Beaton A, et al
    Acute rheumatic fever.
    Lancet. 2025;405:2164-2178.
    >> Share

  13. LARSON H
    Vaccination: a changing political, scientific, and personal landscape.
    Lancet. 2025 Jun 5:S0140-6736(25)01193-6. doi: 10.1016/S0140-6736(25)01193.
    >> Share

    May 2025
  14. ATERE AO, Mustapha FB, Mustapha MJ
    Logistics of the malaria vaccine roll-out in Nigeria.
    Lancet. 2025;405:1815.
    >> Share

    April 2025
  15. MARQUES ETA, Burke DS
    Safety and immunogenicity of a virus-like particle Chikungunya virus vaccine.
    Lancet. 2025;405:1314-1315.
    >> Share

  16. NDEMBI N, Karuna S, Cowden J, Cagigi A, et al
    Accelerating vaccine development in Africa: lessons from HIV research.
    Lancet. 2025 Apr 10:S0140-6736(25)00564-1. doi: 10.1016/S0140-6736(25)00564.
    >> Share

    March 2025
  17. RICHARDSON JS, Anderson DM, Mendy J, Tindale LC, et al
    Chikungunya virus virus-like particle vaccine safety and immunogenicity in adolescents and adults in the USA: a phase 3, randomised, double-blind, placebo-controlled trial.
    Lancet. 2025 Mar 27:S0140-6736(25)00345-9. doi: 10.1016/S0140-6736(25)00345.
    >> Share

  18. TINDALE LC, Richardson JS, Anderson DM, Mendy J, et al
    Chikungunya virus virus-like particle vaccine safety and immunogenicity in adults older than 65 years: a phase 3, randomised, double-blind, placebo-controlled trial.
    Lancet. 2025 Mar 27:S0140-6736(25)00372-1. doi: 10.1016/S0140-6736(25)00372.
    >> Share

  19. MENSAH AA, Whitaker H, Andrews NJ, Watson CH, et al
    Early impact of RSV vaccination in older adults in England.
    Lancet. 2025 Mar 24:S0140-6736(25)00346-0. doi: 10.1016/S0140-6736(25)00346.
    >> Share

  20. DIALLO F, Haidara FC, Tapia MD, Dominguez Islas CP, et al
    Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine targeting serogroups A, C, W, Y, and X when co-administered with routine childhood vaccines at ages 9 months and 15 months in Mali: a single-centre, double-blind, randomised, c
    Lancet. 2025 Mar 11:S0140-6736(25)00046-7. doi: 10.1016/S0140-6736(25)00046.
    >> Share

  21. ALVES L
    Brazil hopes for new vaccine to combat dengue.
    Lancet. 2025;405:770.
    >> Share

    February 2025
  22. PRASAD A
    Sarah Blagden: designing vaccines for cancer prevention.
    Lancet. 2025;405:613.
    >> Share

  23. NEUPANE D, Jaiswal LS, Koirala S
    Nepal set to launch historic HPV vaccination programme.
    Lancet. 2025;405:375.
    >> Share

    January 2025
  24. MUMFORD L, Hogg R, Taylor A, Lanyon P, et al
    Impact of SARS-CoV-2 spike antibody positivity on infection and hospitalisation rates in immunosuppressed populations during the omicron period: the MELODY study.
    Lancet. 2025;405:314-328.
    >> Share

  25. DATOO MS, Hill AVS, Beaumont E, Bradley J, et al
    The R21/Matrix-M malaria vaccine: questions remain - Author's reply.
    Lancet. 2025;405:299-301.
    >> Share

  26. AABY P, Bjorkman A, Schapira A, Benn CS, et al
    The R21/Matrix-M malaria vaccine: questions remain.
    Lancet. 2025;405:299.
    >> Share

  27. OBARO S, Mokuolu O, Michelow IC
    The R21/Matrix-M malaria vaccine: questions remain.
    Lancet. 2025;405:299.
    >> Share

  28. LI Y, Liu G
    The R21/Matrix-M malaria vaccine: questions remain.
    Lancet. 2025;405:298-299.
    >> Share

  29. IMPOUMA B, Adidja A, Mboussou F, Cabore J, et al
    Malaria vaccine introduction in Africa: progress and challenges.
    Lancet. 2025 Jan 21:S0140-6736(24)02841-1. doi: 10.1016/S0140-6736(24)02841.
    >> Share

  30. DZAU V, Hatchett R, Bishen S, Kaseya J, et al
    The time for regionalised vaccine manufacturing has arrived.
    Lancet. 2025 Jan 14:S0140-6736(25)00050-9. doi: 10.1016/S0140-6736(25)00050.
    >> Share

    December 2024
  31. TONY YANG Y
    The perils of RFK Junior's anti-vaccine leadership for public health.
    Lancet. 2024 Dec 18:S0140-6736(24)02603-5. doi: 10.1016/S0140-6736(24)02603.
    >> Share

    November 2024
  32. INO H, Takimoto Y, Nakazawa E
    Misinformation targeting replicon vaccine recipients: an urgent public health ethical issue.
    Lancet. 2024;404:1922-1923.
    >> Share

    October 2024
  33. PAYNE AB, Watts JA, Mitchell PK, Dascomb K, et al
    Respiratory syncytial virus (RSV) vaccine effectiveness against RSV-associated hospitalisations and emergency department encounters among adults aged 60 years and older in the USA, October, 2023, to March, 2024: a test-negative design analysis.
    Lancet. 2024;404:1547-1559.
    >> Share

  34. BRANDA F, Oh J, Acharya KP, Yon DK, et al
    Human vaccination for highly pathogenic avian influenza.
    Lancet. 2024;404:1518-1519.
    >> Share

  35. BRANCHE AR
    Real-world effectiveness studies of the benefit of RSV vaccines.
    Lancet. 2024;404:1498-1500.
    >> Share

  36. ADEPOJU P
    Rwandan Marburg outbreak sparks vaccine efforts.
    Lancet. 2024;404:1389.
    >> Share

  37. QADRI F, Khanam F, Zhang Y, Biswas PK, et al
    5-year vaccine protection following a single dose of Vi-tetanus toxoid conjugate vaccine in Bangladeshi children (TyVOID): a cluster randomised trial.
    Lancet. 2024;404:1419-1429.
    >> Share

  38. AL-MAMUN F, Mamun MA, Roy N
    Long-term efficacy and public health implications of the Vi-tetanus toxoid conjugate vaccine in Bangladeshi children.
    Lancet. 2024;404:1378-1379.
    >> Share

    September 2024
  39. PHUYAL S, Acharya KP, Yon DK
    Antibody titres after vaccination: a missing key to rabies control.
    Lancet. 2024;404:1192-1193.
    >> Share

  40. SALEEM SM, Jan SS
    Operationalising the One Health approach for rabies elimination.
    Lancet. 2024;404:1191-1192.
    >> Share

  41. ADEPOJU P
    Vaccination under way as mpox cases continue to rise.
    Lancet. 2024;404:1184.
    >> Share

  42. MAZUR NI, Caballero MT, Nunes MC
    Severe respiratory syncytial virus infection in children: burden, management, and emerging therapies.
    Lancet. 2024;404:1143-1156.
    >> Share

  43. WALDMAN R, Steinglass R, Nieburg P
    An urgent case for measles vaccination in Gaza.
    Lancet. 2024 Sep 20:S0140-6736(24)02076-2. doi: 10.1016/S0140-6736(24)02076.
    >> Share

  44. PECENKA C, Sparrow E, Feikin DR, Srikantiah P, et al
    Respiratory syncytial virus vaccination and immunoprophylaxis: realising the potential for protection of young children.
    Lancet. 2024 Sep 6:S0140-6736(24)01699-4. doi: 10.1016/S0140-6736(24)01699.
    >> Share

  45. NTUMBA HCK, Mandja BM
    Mpox in eastern Democratic Republic of the Congo: challenges and prospects for vaccination.
    Lancet. 2024 Sep 2:S0140-6736(24)01806-3. doi: 10.1016/S0140-6736(24)01806.
    >> Share

    August 2024
  46. ZHONG L, Zhao Q, Zeng MS, Zhang X, et al
    Prophylactic vaccines against Epstein-Barr virus.
    Lancet. 2024;404:845.
    >> Share

  47. NEUZIL KM, Patel PD, Ndeketa L, Laurens MB, et al
    Efficacy of typhoid conjugate vaccine in Malawian children - Authors' reply.
    Lancet. 2024;404:748.
    >> Share

  48. OBARO S
    Efficacy of typhoid conjugate vaccine in Malawian children.
    Lancet. 2024;404:747-748.
    >> Share

  49. SCHIFFMAN M, de Sanjose S
    The rational design of cervical cancer prevention strategies.
    Lancet. 2024;404:406-407.
    >> Share

    July 2024
  50. ADEPOJU P
    African mpox surges show lack of vaccine access.
    Lancet. 2024;404:18.
    >> Share

    June 2024
  51. LI P, Meng Z, Zhou Z, Zhong Z, et al
    Therapeutic vaccines for Epstein-Barr virus: a way forward.
    Lancet. 2024;403:2779-2780.
    >> Share

  52. HO A, Galgut O, Faustini S, Peters N, et al
    Implications of suboptimal measles immunity in UK health-care workers.
    Lancet. 2024 Jun 26:S0140-6736(24)01011-0. doi: 10.1016/S0140-6736(24)01011.
    >> Share

  53. SAMARASEKERA U
    African vaccine manufacturing scheme to boost production.
    Lancet. 2024;403:2579-2580.
    >> Share

  54. ASHINZE P, Mafua N, Obafemi E
    Nigeria rolls out novel meningitis vaccine.
    Lancet. 2024;403:2373.
    >> Share

    May 2024
  55. LAXMINARAYAN R, Impalli I, Rangarajan R, Cohn J, et al
    Expanding antibiotic, vaccine, and diagnostics development and access to tackle antimicrobial resistance.
    Lancet. 2024 May 20:S0140-6736(24)00878-X. doi: 10.1016/S0140-6736(24)00878.
    >> Share

  56. ADAMU AA, Ndwandwe D, Jalo RI, Muhammad ID, et al
    Cofinancing immunisation through national health insurance.
    Lancet. 2024;403:1983-1984.
    >> Share

  57. SHATTOCK AJ, Johnson HC, Sim SY, Carter A, et al
    Contribution of vaccination to improved survival and health: modelling 50 years of the Expanded Programme on Immunization.
    Lancet. 2024 May 2:S0140-6736(24)00850-X. doi: 10.1016/S0140-6736(24)00850.
    >> Share

    April 2024
  58. COULBORN RM, Danet C, Alsalhani A
    Measles and rubella vaccine microneedle patch: new hope to reach the unreached children.
    Lancet. 2024 Apr 29:S0140-6736(24)00749-9. doi: 10.1016/S0140-6736(24)00749.
    >> Share

  59. ADIGWEME I, Yisa M, Ooko M, Akpalu E, et al
    A measles and rubella vaccine microneedle patch in The Gambia: a phase 1/2, double-blind, double-dummy, randomised, active-controlled, age de-escalation trial.
    Lancet. 2024 Apr 29:S0140-6736(24)00532-4. doi: 10.1016/S0140-6736(24)00532.
    >> Share

  60. ADEPOJU P
    Moderna stalls on African vaccine manufacturing plans.
    Lancet. 2024;403:1617.
    >> Share

  61. ASANTE KP, Mathanga DP, Milligan P, Akech S, et al
    Feasibility, safety, and impact of the RTS,S/AS01(E) malaria vaccine when implemented through national immunisation programmes: evaluation of cluster-randomised introduction of the vaccine in Ghana, Kenya, and Malawi.
    Lancet. 2024 Apr 4:S0140-6736(24)00004-7. doi: 10.1016/S0140-6736(24)00004.
    >> Share

  62. DAUBENBERGER CA, Silva JC
    First-generation malaria vaccine successfully implemented in three African countries.
    Lancet. 2024 Apr 4:S0140-6736(23)02892-1. doi: 10.1016/S0140-6736(23)02892.
    >> Share

    March 2024
  63. RAQIB R
    Bivalent conjugate vaccines for typhoid and paratyphoid fever.
    Lancet. 2024 Mar 28:S0140-6736(24)00461-6. doi: 10.1016/S0140-6736(24)00461.
    >> Share

  64. KULKARNI PS, Potey AV, Bharati S, Kunhihitlu A, et al
    The safety and immunogenicity of a bivalent conjugate vaccine against Salmonella enterica Typhi and Paratyphi A in healthy Indian adults: a phase 1, randomised, active-controlled, double-blind trial.
    Lancet. 2024 Mar 28:S0140-6736(24)00249-6. doi: 10.1016/S0140-6736(24)00249.
    >> Share

  65. BURKI T
    Pivotal tuberculosis vaccine trial begins.
    Lancet. 2024;403:1125.
    >> Share

  66. SHAWE-TAYLOR M, Greenwood D, Hobbs A, Dowgier G, et al
    Divergent performance of vaccines in the UK autumn 2023 COVID-19 booster campaign.
    Lancet. 2024 Mar 11:S0140-6736(24)00316-7. doi: 10.1016/S0140-6736(24)00316.
    >> Share

  67. BURKI T
    The great cholera vaccine shortage.
    Lancet. 2024;403:891-892.
    >> Share

  68. PARHIZ H, Atochina-Vasserman EN, Weissman D
    mRNA-based therapeutics: looking beyond COVID-19 vaccines.
    Lancet. 2024 Mar 7:S0140-6736(23)02444-3. doi: 10.1016/S0140-6736(23)02444.
    >> Share

    February 2024
  69. OCHOGE M, Futa AC, Umesi A, Affleck L, et al
    Safety of the novel oral poliovirus vaccine type 2 (nOPV2) in infants and young children aged 1 to <5 years and lot-to-lot consistency of the immune response to nOPV2 in infants in The Gambia: a phase 3, double-blind, randomised controlled trial.
    Lancet. 2024 Feb 22:S0140-6736(23)02844-1. doi: 10.1016/S0140-6736(23)02844.
    >> Share

  70. COOPER LV, Blake IM
    First Africa-based clinical trial for novel type 2 oral poliovirus vaccine.
    Lancet. 2024 Feb 22:S0140-6736(24)00053-9. doi: 10.1016/S0140-6736(24)00053.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016